News
NOTV
0.8789
-6.53%
-0.0614
Inotiv Is Maintained at Buy by Lake Street
Dow Jones · 18h ago
Inotiv Price Target Cut to $3.00/Share From $5.00 by Lake Street
Dow Jones · 18h ago
Lake Street Maintains Buy on Inotiv, Lowers Price Target to $3
Benzinga · 18h ago
Analysts Offer Insights on Healthcare Companies: Inotiv (NOTV), Eton Pharmaceuticals (ETON) and AxoGen (AXGN)
TipRanks · 22h ago
Lake Street Keeps Their Buy Rating on Inotiv (NOTV)
TipRanks · 22h ago
Inotiv price target lowered to $3 from $5 at Lake Street
TipRanks · 23h ago
Inotiv signals continued DSA revenue growth and margin improvements amid RMS site consolidations and robust awards momentum
Seeking Alpha · 1d ago
Inotiv, Inc. Reports Improved Fiscal 2025 Results
TipRanks · 1d ago
Drug testing services firm Inotiv's Q4 revenue beats estimates
Reuters · 1d ago
*Inotiv 4Q Rev $138.1M >NOTV
Dow Jones · 1d ago
*Inotiv 4Q Loss/Shr 25c >NOTV
Dow Jones · 1d ago
Inotiv Q4 EPS $(0.25) Beats $(0.46) Estimate, Sales $138.142M Beat $135.605M Estimate
Benzinga · 1d ago
BRIEF-Inotiv Q4 Revenue USD 138.1 Million
Reuters · 1d ago
INOTIV REPORTS FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS FOR FISCAL 2025 AND PROVIDES BUSINESS UPDATE
Reuters · 1d ago
Press Release: Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update
Dow Jones · 1d ago
Press Release: Inotiv Reports Fourth Quarter and -3-
Dow Jones · 1d ago
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update
Barchart · 1d ago
Earnings Scheduled For December 3, 2025
Benzinga · 2d ago
Insights Ahead: Inotiv's Quarterly Earnings
Benzinga · 2d ago
Financial Times Reported FDA To End Requirement For Lab Monkeys In Some Drug Safety Studies
Benzinga · 3d ago
More
Webull provides a variety of real-time NOTV stock news. You can receive the latest news about Inotiv Inc through multiple platforms. This information may help you make smarter investment decisions.
About NOTV
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.